Pentadeca Arginate

Pentadeca Arginate is a marketed arginine salt of BPC-157, a synthetic 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV and a molecular weight of 1,419 daltons ¹. The peptide is derived from a protein fragment found in gastric juice ¹. All published efficacy evidence comes from BPC-157 base or unspecified salts; no peer-reviewed study specifically evaluates the arginate salt ¹.

BPC-157 was introduced in the early 1990s as a mediator of the stomach's natural protective response, or cytoprotection. Researchers later extended that protection concept to other organs and tissues ³. Preclinical studies report faster healing in skin, the gastrointestinal tract, tendons, ligaments, muscle, bone, nerves, and cornea ⁴. In humans, evidence is limited to three small uncontrolled pilot studies totaling fewer than 30 people ¹. A separate retrospective knee case series involved 16-17 patients ¹.

The table below summarizes the main research areas.

Indication	Human evidence	Preclinical evidence
Gastrointestinal healing and fistula repair	None	Strong rodent data; unpublished Phase II ulcerative colitis program 4
Tendon and ligament repair	Uncontrolled pilots and case series 22	Strong rodent data 10
Knee pain	Retrospective case series 9	Not applicable
Interstitial cystitis	Pilot case series 8	Not applicable
Muscle and junctional repair	None	Strong rodent data 37

No randomized controlled trial has been completed for any indication, and the arginate salt's stability, absorption, and potential pharmacologic differences remain uncharacterized ¹.

Pentadeca Arginate's pharmacology is extrapolated from BPC-157. The peptide does not act through one identified receptor. Its dominant effect is on blood vessel biology: it promotes blood vessel growth (angiogenesis) and relaxes blood vessels through nitric oxide (NO) signaling ¹⁴.

• VEGFR2-Akt-eNOS. BPC-157 increases production of vascular endothelial growth factor receptor 2 (VEGFR2) in human vascular endothelial cells, promotes its internalization, and activates VEGFR2-Akt-eNOS signaling. In lab assays this increases vessel density and tube formation, and in rats it speeds blood-flow recovery after hindlimb ischemia ¹⁴.
• Src-Caveolin-1-eNOS. Upstream of eNOS, BPC-157 increases phosphorylation of Src, Caveolin-1, and eNOS, and relaxes isolated rat aortas only when the endothelium and NO production are intact ¹⁶.
• Human artery evidence. In human internal mammary artery rings from bypass surgery patients, BPC-157 caused concentration-dependent relaxation of precontracted arteries; this was largely blocked when NO production was inhibited ²⁶.
• FBXO22-BACH1. Cell-level work shows BPC-157 binds the protein FBXO22, which stabilizes the transcription factor BACH1. BACH1 accumulation supports endothelial cell proliferation and tube formation ¹⁵.
• Cytoprotection framework. These endothelial effects are thought to extend stomach protection to whole-organ protection, a concept called organoprotection ³⁰.

Secondary mechanisms reported in preclinical work include fibroblast and tenocyte migration driven by FAK and paxillin phosphorylation ¹¹, growth hormone receptor upregulation in tendon fibroblasts ¹⁷, and ERK1/2 signaling in endothelial cells during alkali-burn healing ²⁷. In animal studies, BPC-157 also reduces some inflammatory cytokines and preserves tissue NO balance in kidney injury models ³².

Evidence for effects is strongest in animals and weakest in humans. Most human findings come from uncontrolled case series and pilots.

• Tendon and ligament healing. Rat studies show faster tendon outgrowth, improved histology, better collagen organization, and functional recovery after Achilles transection ¹⁰. A 2026 rat Achilles study found numeric improvements in histology and collagen with BPC-157, but the load-to-failure gain compared with controls did not reach statistical significance for BPC-157 alone ¹⁰.
• Gastrointestinal healing. In rodents, BPC-157 accelerates healing of stomach and intestinal injury and supports fistula closure ⁴.
• Spinal cord injury. Single-dose intraperitoneal treatment after spinal cord compression improved functional recovery in rats through long-term follow-up ³⁶.
• Pain. Rat incisional-pain models show a raised pain threshold within 2 hours of a single dose ³⁵. A retrospective knee-pain series reported significant improvement in 11 of 12 patients after intra-articular injection ⁹.
• Bladder symptoms. In one pilot, a single intravesical dose improved symptoms in 10 of 12 women with interstitial cystitis ⁸.
• Blood vessel protection. BPC-157 relaxes human arteries through NO and promotes collateral vessel recruitment after occlusion in animal models ³.

The true magnitude of these effects in humans remains unproven because no randomized controlled trial has been completed ⁶.

Research protocols span preclinical rodent work, small human pilots, and community schedules. The highest human evidence is uncontrolled.

• Preclinical anchor. Many rodent studies use 10 mcg/kg or 10 ng/kg daily by intraperitoneal, intragastric, or drinking-water routes, with roughly similar results at both dose levels ⁴. A rat Achilles transection study used 10 mcg/kg intraperitoneally once daily for 4 weeks ¹⁰.
• Human pilot schedules. An intravenous safety pilot gave 10 mg on day 1 and 20 mg on day 2 as one-hour infusions ⁷. An interstitial cystitis pilot used a single 10 mg intravesical injection ⁸. A retrospective knee series used single intra-articular injections with no standardized dose ⁹.
• Community subcutaneous protocols. Community protocols typically start at 250 mcg once daily for conservative entry, then move to 250 mcg twice daily (500 mcg/day total) for 6-8 weeks ¹. Body-weight scaling around 2.5-3.5 mcg/kg/day is a common convention ¹.
• Oral protocols. Community oral use runs 250-1,000 mcg/day, supported by animal studies showing oral activity because the peptide is stable in gastric juice for more than 24 hours ³.
• Timing. Plasma half-life is under 30 minutes, but biologic effects persist for hours to days. Community protocols therefore favor split daily dosing, such as twice daily ¹.
• Duration. Community cycles are commonly 4-8 weeks on with a 2-4 week break, anchored to 4-week rodent tendon studies and up to 90-day oral junctional repair studies ¹⁰.

BPC-157 is supplied as a lyophilized powder for research use. Community protocols describe bacteriostatic water (0.9% benzyl alcohol) as the standard diluent; sterile water is acceptable for single-use vials. The powder is dissolved by adding diluent slowly against the vial wall and rolling gently. Shaking should be avoided.

Storage recommendations are based on the parent peptide because no published stability data exist for the arginate salt ¹. Unreconstituted powder is kept frozen at -20°C for long-term storage or refrigerated at 2-8°C for shorter periods, dry and protected from light. After reconstitution, vials are refrigerated and typically used within 14-30 days.

In blood matrices, BPC-157 remains stable frozen at -20°C for at least 2 months, and dried-spot samples remain detectable without refrigeration ⁶¹. Once in plasma, the peptide is rapidly broken down into small fragments and amino acids, with a plasma half-life under 30 minutes ². This rapid clearance does not predict the duration of biologic effects, which can last much longer ¹.

Most interaction data are preclinical; no formal human drug interaction studies exist for any BPC-157 salt form. The dominant pattern in animals is that BPC-157 counteracts drug-induced toxicity rather than producing new toxicity itself.

• NSAIDs. In rats, BPC-157 reduced gastrointestinal, liver, and brain lesions from NSAIDs and celecoxib ⁵². This is a toxicity-counteraction signal, not an established human interaction.
• Anticoagulants and antiplatelets. Animal studies show reduced bleeding and preserved platelet counts after heparin or warfarin, while some clot assays remained unchanged ⁴⁴. BPC-157 partially reversed antiplatelet effects of aspirin, clopidogrel, and cilostazol in rats ⁴⁵.
• Corticosteroids. BPC-157 opposed methylprednisolone's delay of tendon-to-bone healing in rats ⁵⁴.
• Anesthetics and analgesics. In animal models it shortened thiopental anesthesia ⁴³, shortened lidocaine and bupivacaine nerve blockade ⁴⁸, and reduced morphine analgesia in mice ⁵⁷.
• Psychiatric and cardiac drugs. Rat studies show BPC-157 counteracts QTc prolongation from several antipsychotics ⁵⁰ and protects against gentamicin-induced kidney injury through NO-system modulation ³². It also mitigated lithium toxicity in rats ⁵⁵.
• Theoretical interactions. Because BPC-157 relaxes human arteries through NO, additive blood pressure lowering with vasodilators is plausible ²⁶. BPC-157 is a weak acetylcholinesterase inhibitor with millimolar potency, so meaningful cholinergic overlap is unlikely at research-range doses ²⁹. Dopamine-system drug interactions have extensive preclinical data (neuroleptics, amphetamine), with limited rodent data for one SSRI combination (citalopram) and one nitrate (isosorbide mononitrate), but no formal human drug-interaction studies exist for any of these classes.

No randomized trial defines an optimal cycle for Pentadeca Arginate. Community protocols typically use 4-8 weeks on followed by 2-4 weeks off ¹. The on-period is anchored to preclinical courses: a rat Achilles study used 4 weeks of daily dosing ¹⁰, and a rat muscle-to-bone reattachment study used 90 days of oral dosing ³⁷. Practitioner consensus generally caps continuous use at 8-12 weeks with a minimum 2-week gap between cycles ¹.

Breaks are not based on documented tolerance. Animal and pilot evidence does not report tachyphylaxis, and the sub-30-minute plasma half-life ² means drug accumulation is unlikely. Instead, cycling caps cumulative exposure to pro-angiogenic pathways with unresolved long-term safety ¹⁹.

Signals for a break in community practice include a plateau in benefit for about two consecutive weeks, new persistent symptoms, or any change in skin lesions given the peptide's blood-vessel-promoting mechanism ¹⁵. No validated chronic biomarker panel exists, but baseline and post-cycle bloodwork is common community practice ¹⁸.

Common combinations reported in research and community use include TB-500, growth hormone secretagogues, and GHK-Cu, but direct combination evidence is limited.

• TB-500 (TB-4). In a rat Achilles model, BPC-157 plus TB-500 produced no additive biomechanical or histologic benefit over either agent alone ¹⁰. The mechanisms are different: BPC-157 drives angiogenesis partly through VEGFR2 and BACH1 ¹⁴, while TB-4 primarily affects cell migration.
• GH secretagogues. BPC-157 upregulates growth hormone receptor in tendon fibroblasts and enhances growth-hormone-stimulated proliferation ¹⁷. Combinations with ipamorelin or CJC-1295 are common in practitioner consensus, but no human synergy data exist.
• GHK-Cu. This copper peptide works through distinct wound-healing pathways and is frequently combined, but no direct interaction studies exist.
• GLP-1 agonists. Compounded BPC-157 and GLP-1 combinations have been marketed, and regulators have flagged BPC-157 as unsafe for compounding ²⁵. No pharmacodynamic interaction data exist.
• NO-system caution. Because BPC-157's effects depend on nitric oxide signaling, community protocols advise against stacking multiple NO-modulating agents ⁵⁹.

Pentadeca Arginate is not approved by the FDA or EMA for any indication ⁵. No validated formulation or dosing regimen exists, and all published human data come from fewer than 30 subjects in uncontrolled pilot studies ¹. In the United States, the FDA has determined that BPC-157 is unsafe for pharmacy compounding, and it has appeared in compounded-product enforcement contexts ²⁵. Control operates through unapproved-new-drug and compounding restrictions rather than controlled-substance scheduling ²⁵.

No EMA marketing authorization exists, and national import rules generally default to prohibition for unapproved injectables ⁵. Distribution outside approved channels carries documented impurity and dosing risks ¹⁹.

In sports, WADA temporarily banned BPC-157 in 2022. One source reports it is not currently listed, while a 2025 review places it under WADA Class S0 for unapproved substances ⁵. Because status has fluctuated, athletes should assume it is prohibited. Detection methods are mature, with dried-blood-spot and plasma workflows detecting BPC-157 at low nanogram levels ⁶¹.

Overall, preclinical toxicology is reassuring but human exposure is tiny and uncontrolled. No serious toxicity, genetic toxicity, or embryo-fetal toxicity appeared in multi-species preclinical safety testing ¹⁸. The only treatment-related finding was mild injection-site irritation ¹⁸. In three published human pilots, no adverse events were reported after intravenous, intravesical, or intra-articular use ⁷, but these studies together included fewer than 30 people and no randomized controlled trial exists ²².

Community users report transient injection-site stinging, redness, bruising, brief headache, mild nausea, fatigue, and sleep changes, usually resolving within the first days of use. These reports come from uncontrolled community experience, not trial data. In dogs, repeated 2 mg/kg dosing lowered serum creatinine reversibly, with no sign of kidney toxicity ¹⁸.

Rare or theoretical concerns include:

• Tumor and angiogenesis risk. Pro-angiogenic signaling raises a theoretical concern about supporting hidden cancers ¹⁹. Some preclinical work argues BPC-157 supports controlled rather than pathological angiogenesis, but human data are absent ⁵⁸.
• Contamination and quality. Unregulated products carry risks of impurities, inaccurate dosing, and contamination ¹⁹. The FDA has deemed BPC-157 unsafe for compounding ²⁵.
• Anesthesia interaction. BPC-157 antagonized thiopental anesthesia in rats ⁴³; relevance to other anesthetics is unknown.
• Bleeding modulation. Animal data show reduced bleeding and preserved platelet counts after anticoagulants ⁴⁴; the clinical meaning is unknown.

Contraindications from the literature are pregnancy and breastfeeding, known hypersensitivity, and any setting requiring anti-doping compliance. Relative cautions include active or recently treated malignancy, scheduled surgery, and concurrent anticoagulant or antiplatelet therapy ¹⁹.